Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tris Pharma Inc.

www.trispharma.com

Latest From Coulter Pharmaceutical Inc.

In-Licensing Pays Off for Big Pharma

In-licensing has become central to Big Pharma's strategy for growth, and it's paying off more than ever.
BioPharmaceutical

Chiron at the Crossroads

Three years into a new CEO's regime, Chiron is trying to forge a unique compromise between research and commercial focus and the stability which comes from a diversified business. But Chiron is at a crossroads: its earnings growth, boosted significantly by a now complete cost-reduction program, doesn't look sustainable without major new products. And those Chiron does not appear to have. Moreover, its major shareholder, Novartis, has an option to buy the company and top management fears they will should the stock show significant signs of weakness, brought on, perhaps, by investments (and consequent earnings reductions) in potential high-growth areas. In effect, Chiron managers are afraid to invest significantly for fear of what Novartis will do should the stock price fall. Moreover, to some degree, Chiron is caught by its business diversity: it can't focus its spending on any one area, particularly biopharmaceuticals, without starving its other businesses--but without a significant increase in R&D spending, particularly in the drug unit, observers don't see how Chiron, which has been uniquely unsuccessful with its pipeline projects, can drive the long-term earnings growth it needs.
BioPharmaceutical Medical Device

Deal Statistics Quarterly, Nov 2000-Jan 2001

In Vivo presents another installment of our quarterly review of dealmaking--in this case November 2000-January 2001. Our data comes from Windhover's Strategic Transactions Database. We include medical device financings by industry segment and by deal type; medical device M&A; diagnostic financings and alliances by product category; pharma and biotech alliances by technology segment; pharma and biotech alliances by deal type, and pharma and biotech financings by market segment and therapeutic category.
BioPharmaceutical Medical Device

Genitope Corp.

Genitope is using a novel gene expression technology in cancer immunotherapy. Starting with a tumor sample, it produces patient-specific idiotype antibodies which target B cell tumors and stimulate an immune response. The strategy is equivalent to that used in over a decade of clinical studies by Ron Levy of Stanford University, who encouraged Genitope founder Dan Denney to start the company.
BioPharmaceutical
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Tris Pharma Inc.
  • Senior Management
  • Ketan Mehta, Pres. & CEO
    Mahdi Fawzi, PhD, EVP, CSO
    Jonathan Berlent, VP, Bus. Dev.
    Yu-Hsing Tu, VP, R&D
    Adam Drapczuk, Dir., Fin.
  • Contact Info
  • Tris Pharma Inc.
    Phone: (732) 940-2800
    2033 Route 130, Ste. D
    Monmouth Junction , NJ 08852
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register